RayKnowChina Research Map
Shortlist

KunmingKunming Medical University

First Affiliated Hospital of Kunming Medical University

昆明医科大学第一附属医院

Listed for 20 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Kunming Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌6 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  3. Lung cancer肺癌45 papers led2 open trials led
  4. Glioma胶质瘤16 papers led
  5. Osteosarcoma骨肉瘤2 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Neuroblastoma神经母细胞瘤3 papers led
  8. Multiple myeloma多发性骨髓瘤0 papers led
  9. Beta thalassaemiaβ 地中海贫血0 papers led
  10. Haemophilia A血友病 A1 paper led
  11. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病1 paper led
  12. Moyamoya disease烟雾病2 papers led
  13. Coronary heart disease冠心病4 papers led
  14. Congenital heart disease先天性心脏病6 papers led1 open trial led
  15. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  16. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  17. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  18. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  19. Hereditary angioedema遗传性血管性水肿0 papers led
  20. Familial adenomatous polyposis家族性腺瘤性息肉病3 papers led

Not listed for: Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Myasthenia gravis, Wilson disease, Biliary atresia, Scoliosis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 332025

3 hospitals in Kunming for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

  2. Recruiting
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07328854

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueImaging & AI
Departments in papersRadiation oncologyENT / head & neck surgeryRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led6
  1. Delineation of reduced CTV2 on the basis of the characteristics and distribution of cervical lymph node metastasis in nasopharyngeal carcinoma.2025BMC cancerFree full text
  2. HNMT Promotes the Occurrence and Progression of Nasopharyngeal Carcinoma by Inhibiting the IFN/TXNIP/p53 Axis.2025Current medical science
  3. CircCENPM serves as a CeRNA to aggravate nasopharyngeal carcinoma metastasis and stemness via enhancing BMI1.2025HereditasFree full text
  4. M6A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma.2024Cancer biology & therapyFree full text
  5. miR-128-3p increases the radiosensitivity in nasopharyngeal carcinoma via regulating vascular endothelial growth factor C.2023Pathology, research and practice
  6. The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study.2022Radiation oncology (London, England)Free full text
All its trials on ClinicalTrials.gov, any status4
  1. Clincal Study of Reduced Target Radiotherapy in Nasopharyngeal CarcinomaCompletedNCT05741008Lead sponsorN/AStart 2023-01
  2. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  3. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  4. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
More papers found outside PubMed (not counted)2
  1. 663P Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study2022Annals of Oncologyarticle
  2. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

2 hospitals in Kunming for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIImmunotherapy
Departments in papersRadiation oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 45 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
45
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 6620222023: 8820232024: 111120242025: 12122025

2 hospitals in Kunming for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Epidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung Cancer
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT06775821

    Age 20 years to 90 years (registered criteria)

    Led by First Affiliated Hospital of Kunming Medical University; 1 listed hospital as study siteKunming

  2. Enrolling by invitation
    The Effect of Esketamine Combined With Dexmedetomidine on Postoperative Recovery Quality in Patients Undergoing Thoracoscopic Surgery
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT07125573

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Kunming Medical UniversityKunming

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineRadiation oncologyNeurosurgery
Papers it led45
  1. ACSM5 c.1273 C> A Polymorphism Promotes Malignant Progression of Lung Adenocarcinoma in Xuanwei Region.2026Applied biochemistry and biotechnology
  2. Spatial Location of SPP1+TAMs and Mutually Exclusive Subsets Based on Single-Cell and Transcriptome Data.2026Cancer scienceFree full text
  3. ACTG1 mediates cisplatin resistance in NSCLC through induction of mitochondrial fragmentation.2025Apoptosis : an international journal on programmed cell death
  4. Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancer.2025BMC cancerFree full text
  5. Overexpression of METTL3 in lung cancer cells inhibits radiation-induced bystander effect.2025Biochemical and biophysical research communications
  6. Isolated Adrenocorticotropic Hormone Deficiency Associated with Sintilimab in the Treatment of Lung Adenocarcinoma: A Case Report and Literature Review.2025Endocrine research
  7. The role of histone methyltransferases in therapeutic resistance of NSCLC.2025EpigeneticsFree full text
  8. Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinoma.2025Frontiers in immunologyFree full text
  9. Management strategies for primary lung carcinosarcoma: a case study and comprehensive literature review.2025Journal of cancer research and clinical oncologyFree full text
  10. Induction of necroptosis in lung adenocarcinoma by miR‑10b‑5p through modulation of the PKP3/RIPK3/MLKL cascade.2025Oncology reportsFree full text
  11. Cisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignant pleural mesothelioma: Temporal dynamics revealed by cellular and xenograft analyses.2025Pathology, research and practice
  12. Artificial intelligence-based CT histogram parameters differentiating bronchiolar adenoma and lung adenocarcinomas: A two-center study.2025PloS oneFree full text
  13. Keratin 80 as a diagnostic biomarker with limited prognostic value in non-small cell lung cancer.2025Scientific reportsFree full text
  14. Effects of primary tumor location in the basal segment or superior segment (S6) on patient survival in lung cancer: a meta-analysis.2025World journal of surgical oncologyFree full text
  15. Usenamine A triggers NLRP3/caspase-1/GSDMD-mediated pyroptosis in lung adenocarcinoma by targeting the DDX3X/SQSTM1 axis.2024AgingFree full text
  16. Complement Factor B (CFB) inhibits the malignant progression of lung adenocarcinoma by downregulating the Ras/MAPK signaling pathway.2024Archives of biochemistry and biophysics
  17. An artificial intelligence algorithm for the detection of pulmonary ground-glass nodules on spectral detector CT: performance on virtual monochromatic images.2024BMC medical imagingFree full text
  18. Expression patterns and prognostic role of m6A RNA methylation regulators in Non-small Cell Lung Cancer.2024Cellular and molecular biology (Noisy-le-Grand, France)
  19. Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non-small cell lung cancer.2024Clinical and translational medicineFree full text
  20. Mechanisms of Bone Morphogenetic Protein 2 in Respiratory Diseases.2024Current allergy and asthma reports
  21. Blocking lncRNA HCG18 re-sensitizes Taxol resistant lung cancer cells to Taxol through modulating the miR-34a-5p/HDAC1 axis.2024Journal of chemotherapy (Florence, Italy)
  22. Exosome miR-101-3p derived from bone marrow mesenchymal stem cells promotes radiotherapy sensitivity in non-small cell lung cancer by regulating DNA damage repair and autophagy levels through EZH2.2024Pathology, research and practice
  23. Causal role of metabolites in non-small cell lung cancer: Mendelian randomization (MR) study.2024PloS oneFree full text
  24. Identification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma.2024Scientific reportsFree full text
  25. Signal Transducer and Activator of Transcription 4-Induced Up-Regulated LINC01278 Enhances Proliferation and Invasion of Non-Small Cell Lung Cancer Cells via the MicroRNA-877-5p/Activating Transcription Factor 4 Axis.2024Tissue engineering and regenerative medicineFree full text
  26. Advanced lung cancer inflammation index combined with geriatric nutritional risk index predict all-cause mortality in heart failure patients.2023BMC cardiovascular disordersFree full text
  27. M2 macrophages-derived exosomal miR-3917 promotes the progression of lung cancer via targeting GRK6.2023Biological chemistry
  28. Cognitive changes are associated with increased blood-brain barrier leakage in non-brain metastases lung cancer patients.2023Brain imaging and behaviorFree full text
  29. Characteristics of the microbiome in lung adenocarcinoma tissue from patients in Kunming city of southwestern China.2023Environmental science and pollution research international
  30. ELANE Promotes M2 Macrophage Polarization by Down-Regulating PTEN and Participates in the Lung Cancer Progression.2023Immunological investigations
  31. Dual-layer spectral detector CT (SDCT) can improve the detection of mixed ground-glass lung nodules.2023Journal of cancer research and clinical oncologyFree full text
  32. Nucleophosmin promotes lung adenocarcinoma cell proliferation, migration and invasion by activating the EGFR/MAPK signaling pathway.2023Oncology reportsFree full text
  33. Pan-cancer landscape of CENPO and its underlying mechanism in LUAD.2023Respiratory researchFree full text
  34. Knockdown of mitochondrial threonyl-tRNA synthetase 2 inhibits lung adenocarcinoma cell proliferation and induces apoptosis.2022BioengineeredFree full text
  35. miR-26a-5p Suppresses Wnt/β-Catenin Signaling Pathway by Inhibiting DNMT3A-Mediated SFRP1 Methylation and Inhibits Cancer Stem Cell-Like Properties of NSCLC.2022Disease markersFree full text
  36. Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers.2022Frontiers in immunologyFree full text
  37. Bioinformatics Identification of Key Genes for the Development and Prognosis of Lung Adenocarcinoma.2022Inquiry : a journal of medical care organization, provision and financingFree full text
  38. Pyroptosis in inflammation-related respiratory disease.2022Journal of physiology and biochemistryFree full text
  39. Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.2022Thoracic cancerFree full text
  40. Cox15 is a novel oncogene that required for lung cancer cell proliferation.2021Biochemical and biophysical research communications
  41. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.2021Cancer medicineFree full text
  42. Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation.2021Lung cancer (Amsterdam, Netherlands)
  43. Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing.2021Neoplasia (New York, N.Y.)Free full text
  44. Integrated Analysis of lncRNAs and mRNAs Identifies a Potential Driver lncRNA FENDRR in Lung Cancer in Xuanwei, China.2021Nutrition and cancer
  45. miR-133b targets NCAPH to promote β-catenin degradation and reduce cancer stem cell maintenance in non-small cell lung cancer.2021Signal transduction and targeted therapyFree full text
Chinese-language papers (not in the count)7
  1. [Advances in the Treatment of Multiple Primary Lung Cancer].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Application Research of Serum miR-4646-5p, miR-3654 Combined with Traditional Lung Cancer Tumor Markers in the Diagnosis of Lung Cancer in Xuanwei, Yunnan Province].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  3. [Role of COX-2/PGE2/EP4 Axis-induced Macrophage Functional Activation 
in NSCLC Development].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  4. [Research advances in tissue-resident macrophages and monocyte-derived macrophages in lung cancer].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Leptin-mediated ERK Signaling Pathway Promotes the Transformation 
of Rat Alveolar Type II Epithelial Cells Induced by Yunnan Tin Mine Dust].2023Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  6. [Research advances in non-terminal respiratory unit adenocarcinoma of the lung].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  7. [Development and validation of prognostic nomogram for malignant pleural mesothelioma].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status4
  1. The Effect of Esketamine Combined With Dexmedetomidine on Postoperative Recovery Quality in Patients Undergoing Thoracoscopic SurgeryEnrolling by invitationNCT07125573Lead sponsorN/AStart 2025-05
  2. Epidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung CancerRecruitingNCT06775821Lead sponsorStart 2022-10
  3. Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)Active, not recruitingNCT06577792Study siteN/AStart 2023-08
  4. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 16 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.2%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 2220232024: 2220242025: 442025

2 hospitals in Kunming for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryPathology / laboratory medicineNeurologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led16
  1. SHANK1 is epigenetically silenced by EZH2 and suppresses Wnt/β-catenin signaling to inhibit glioblastoma stem cell maintenance.2025Biochemical and biophysical research communications
  2. Hypoxia induced SH3GLB1 is required for NOTCH2 activation and glioblastoma development.2025Biochemical and biophysical research communications
  3. Multifocal medulloblastoma in an adult: a case report and review of the literature.2025Journal of cancer research and clinical oncologyFree full text
  4. High-definition fusion of multi-modal images of brain gliomas based on AKS-SRNet.2025The Review of scientific instruments
  5. Pilocytic Astrocytoma of the fourth ventricle: A case report.2024Asian journal of surgery
  6. Expression patterns and prognostic role of m6A RNA methylation regulators in Non-small Cell Lung Cancer.2024Cellular and molecular biology (Noisy-le-Grand, France)
  7. GALNT2 sustains glioma stem cells by promoting CD44 expression.2023AgingFree full text
  8. Case report of epileptic seizure during awake craniotomy of functional area glioma and literature study.2023International review of neurobiology
  9. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.2022AgingFree full text
  10. DNA topoisomerase II alpha promotes the metastatic characteristics of glioma cells by transcriptionally activating β-catenin.2022BioengineeredFree full text
  11. The Reactive Astrocytes After Surgical Brain Injury Potentiates the Migration, Invasion, and Angiogenesis of C6 Glioma.2022World neurosurgery
  12. SH3BGRL3, transcribed by STAT3, facilitates glioblastoma tumorigenesis by activating STAT3 signaling.2021Biochemical and biophysical research communications
  13. SH3BGRL2 functions as a crucial tumor suppressor in glioblastoma tumorigenesis.2021Biochemical and biophysical research communications
  14. SH3GL3 acts as a novel tumor suppressor in glioblastoma tumorigenesis by inhibiting STAT3 signaling.2021Biochemical and biophysical research communications
  15. CircPITX1 Regulates Proliferation, Angiogenesis, Migration, Invasion, and Cell Cycle of Human Glioblastoma Cells by Targeting miR-584-5p/KPNB1 Axis.2021Journal of molecular neuroscience : MN
  16. Sevoflurane inhibits cell proliferation and migration of glioma by targeting the miR‑27b/VEGF axis.2021Molecular medicine reportsFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Validity and Reliability Evaluation of the PRO-CTCAE for Adult-type Diffuse Gliomas Patients in Chinese PopulationCompletedNCT05486923Study siteStart 2022-09

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

8 hospitals in Kunming for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology
Papers it led2
  1. AZD1080, a specific inhibitor of GSK‑3β, inhibits stemness and malignancies in osteosarcoma cancer stem‑like cells.2025Molecular medicine reportsFree full text
  2. Circle RNA circCSPP1 promotes human osteosarcoma cell proliferation and increases glucose metabolism by suppressing miR-200c maturation.2022Human & experimental toxicology
Chinese-language papers (not in the count)1
  1. [Extraskeletal osteosarcoma in lymph nodes: a case report].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
Earlier papers (2016–2020)8
  1. Polydatin enhances the chemosensitivity of osteosarcoma cells to paclitaxel.2019Journal of cellular biochemistry
  2. Long non-coding RNA SNHG5 sponges miR-26a to promote the tumorigenesis of osteosarcoma by targeting ROCK1.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  3. GAPLINC is a predictor of poor prognosis and regulates cell migration and invasion in osteosarcoma.2018Bioscience reports
  4. miRNA-1284, a regulator of HMGB1, inhibits cell proliferation and migration in osteosarcoma.2018Bioscience reports
  5. LncRNA CCAT2 enhances cell proliferation via GSK3β/β-catenin signaling pathway in human osteosarcoma.2018European review for medical and pharmacological sciences
  6. MicroRNA485-3p negatively regulates the transcriptional co-repressor CtBP1 to control the oncogenic process in osteosarcoma cells.2018International journal of biological sciences
  7. DNA Methylation Mediated Downregulation of miR-449c Controls Osteosarcoma Cell Cycle Progression by Directly Targeting Oncogene c-Myc.2017International journal of biological sciences
  8. miR-10b promotes invasion by targeting KLF4 in osteosarcoma cells.2016Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Kunming for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

5 hospitals in Kunming for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led no English-language PubMed papers on multiple myeloma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution

2 hospitals in Kunming for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  2. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Posted
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  3. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Kunming for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Analysis of Genetic Test Results and Red Blood Cell Parameters of β-Thalassemia in Kunming Area].2025Zhongguo shi yan xue ye xue za zhi

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Kunming for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 1 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Kunming for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

  2. Not yet recruiting
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    Phase
    Phase 4
    Started
    2026-06
    Posted
    Registry
    NCT07699770

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAcute attack treatmentAntibodies & diagnosis
Papers it led1
  1. Double-negative neuromyelitis optica spectrum disorder.2023Multiple sclerosis (Houndmills, Basingstoke, England)Free full text
All its trials on ClinicalTrials.gov, any status3
  1. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory TrialNot yet recruitingNCT07699770Study sitePhase 4Start 2026-06
  2. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  3. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Kunming for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRevascularisation surgeryImaging & blood flowStroke & bleeding outcomes
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 4 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.08%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

3 hospitals in Kunming for coronary heart disease231 hospitals in China for coronary heart disease

No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 6 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 222025

7 hospitals in Kunming for congenital heart disease207 hospitals in China for congenital heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Design and Application of a Home Care WeChat Mini-Program for Children After Congenital Heart Disease Surgery
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07385209

    Age 0 years to 12 years (registered criteria)

    Led by First Affiliated Hospital of Kunming Medical UniversityKunming

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Kunming for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

6 hospitals in Kunming for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Kunming for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Kunming for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Kunming for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruitingNCT06846398Study sitePhase 2Start 2025-02
  2. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 3 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 5.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

3 hospitals in Kunming for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

昆明医科大学第一附属医院

First Affiliated Hospital of Kunming Medical University

昆明

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
First Affiliated Hospital of Kunming Medical College

Suggest a correctionDownload the data